RT Journal Article
SR Electronic
T1 International attitudes on COVID-19 vaccination: repeat national cross-sectional surveys across 15 countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.08.21252449
DO 10.1101/2021.03.08.21252449
A1 Crespo, Roberto Fernandez
A1 Shafat, Manar
A1 Melas-Kyriazi, Natalie
A1 Gould, Lisa
A1 Jones, Sarah
A1 Neves, Ana Luisa
A1 Leis, Melanie S
A1 Maheswaran, Hendramoorthy
A1 Darzi, Ara
YR 2021
UL http://medrxiv.org/content/early/2021/03/27/2021.03.08.21252449.abstract
AB Objective To examine the general public’s views around willingness to receive COVID-19 vaccines and concerns regarding their safety.Design Repeat cross-sectional surveys.Setting Online surveys in Australia, Canada, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Norway, Singapore, South Korea, Spain, Sweden and the United KingdomParticipants National samples of adults aged >=18 years in November 2020 and January 2021.Main outcomes measures The proportion of adults reporting: willingness to receive a COVID-19 vaccination; concern regarding side-effects from vaccinations; concerns over contraction COVID-19, and beliefs around vaccine provision in their country. Changes between the November and January surveys are also reported.Results Across the 15 countries, the proportion of respondents reporting they would have the COVID-19 vaccine increased from 40.7% (range: 25.0-55.1) to 55.2% (range: 34.8-77.5), proportion reporting worried about the side-effects of vaccine decreased from 53.3% (range: 42.1-66.7) to 47.9% (range: 28.0-66.1). On the second survey, willingness to receive vaccine remained low in females (49.4%, range: 30.2-79.1), aged 18-39 years (42.1%, range: 25.9-71.7), those not working or unemployed (48.9, range: 18.8-67.0), students (45.9%, range: 22.8-70.0), and those with children at home (46.5%, range: 32.4-68.9). Concerns regarding safety of vaccine remained high in females (53.7%, range: 31.8-70.4), aged 18-39 years (50.8%, range: 28.2-60.7), aged 40-64 years (51.3%, range: 30.7-68.5), those working (50.5%, range: 26.7-65.0), those not working or unemployed (53.3, range: 35.4-73.8) and those with children at home (55.8%, range: 36.5-64.7).Conclusion COVID-19 vaccine hesitancy decreased considerably over a relatively short time coinciding with the discovery of effective vaccines. The public remain concerned about their safety, and public health messaging will need to emphasis their safety especially amongst females, parents and younger adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo sources of funding to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not needed. All data for YouGov surveys are deidentified and publicly available from: https://github.com/YouGov-Data/covid-19-tracker All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for YouGov surveys are deidentified and publicly available from: https://github.com/YouGov-Data/covid-19-tracker https://github.com/YouGov-Data/covid-19-tracker